PSA Rising-and Falling!
Let me start by congratulating my editorial staff, editorial and advisory board, and each of you who have contributed to the journal in some manner. We have very recently learned that Integrative Cancer Therapies (ICT) has been accepted by the Institute for Scientific Information (ISI) as part of their master journal list. The ISI is a crucial resource in the academic world. Run by Thompson Scientific, it offers a wide variety of scientific information services, one of the best-known of which is the journal impact factor. The impact factor is a measurement of how influential a journal is in the scientific publishing community, based on the number of times that articles in the journal are cited by other journal articles. Inclusion in the ISI is a powerful sign that ICT is becoming an important player in the world of scientific information resources, since not all medical journals are included in this database. We have learned from our publisher that only 8% of medical journals ever receive this acclaim. We thank and salute our authors for their contribution of influential articles and hope to see many more such articles.
Two articles in this issue will surely add to future measures of ICT's impact factor. Gordon Saxe and his colleagues at the University of California, San Diego, have contributed 2 articles concerning a pilot clinical study of a plant-based diet and a stress management program in patients with biochemical recurrence of prostate cancer (ie, rising prostate-specific antigen [PSA] after completing initial conventional treatment). Rising PSAs usually indicate advancing disease, which can eventually result in frank metastases, with a fatal outcome for a proportion of patients. The current treatment option for this situation-hormonal therapy-is unsatisfactory both qualitatively and quantitatively, especially for patients whose rate of PSA increase is slow.
The first of these articles concerns the clinical impact of a diet program on PSA levels. The dietary intervention is consonant with a similar program that we and other integrative clinics have been recommending for many years, and this work reinforces the direction many of us have taken. Saxe and colleagues report a major slowing in the rate at which PSA levels rose, compared to the rate of increase before the study. This is an extremely important finding for patients with biochemical recurrence. Some of the patients even had a noticeable drop in PSA, rather than just a slower rate of increase. This drop indicates a possible regression in disease, similar to what would be seen with hormonal therapy but without its very negative side effects. The second article details the dietary changes patients made and an intriguing correlation of rates of PSA increase with adherence to the diet program. Saxe's study adds significantly to the emerging literature on dietary management of prostate cancer and is surely a major impetus to proceed with further clinical research in this area. My research team at the Block Center for Integrative Cancer Treatment is currently working on a manuscript describing lengthened survival times in stage D2 prostate cancer patients using a plant-based diet, exercise, and mind-spirit and supplementation program, which we hope will serve to reinforce Saxe's interventional study. Prostate cancer patients and their physicians should certainly take note of this emerging body of science on the contributions of diet to potential control of this very widespread disease, and researchers need to work on extending and expanding work in this area.
This issue also has an abundance of other riches, including some review articles that should be of especially wide interest. Aditya Bardia, Amit Sood, and colleagues from the Mayo Clinic have contributed a useful systematic review on the topic of optimal Medline searches for information on complementary medicine in cancer. Patrick Mansky and colleagues at the National Center for Complementary and Alternative Medicine have systematically reviewed the topic of tai chi chuan for cancer survivors, a very popular exercise and mind-body modality. Constance Visovsky, University of Omaha, reviews and analyzes the literature on muscle strength, body composition, and physical activity in breast cancer chemotherapy patients. In a staff article, Mark McCarty and I review the potential of salicylates, suppressors of NF-κB, to increase chemosensitivity of tumors.
The issue also includes 2 laboratory-based articles. In one article, Mandy King, Stuart Adler, and Laura Murphy of Southern Illinois University discuss the detection of estrogen receptor binding activity in particular types of American ginseng extracts, a topic that will be of interest to health professionals treating breast cancer patients. K. Sheeja and Girija Kuttan of the Amala Cancer Research Institute present an evaluation of Kan Jang, Andrographis paniculata, as a possible protectant against urothelial toxicity of cyclophosphamide.
Two articles explore the ever-interesting topic of patterns of use of complementary medicine by cancer patients. Danette Hann and colleagues question whether patients' satisfaction with their treating oncologist influences their decisions to use complementary and alternative medicine (CAM), an article that will certainly be of interest to all CAM and integrative medicine practitioners whose patients have come to them claiming to have had difficulties with their treating oncologists. Philip Tovey and colleagues have investigated this question in an unusual group that certainly deserves more attention than it usually receives: low-income cancer patients at an urban cancer center in Brazil. This represents another in a series of studies by Tovey and his colleagues on international patterns of CAM use.
We have the great pleasure of announcing 2 special issues for December 2006 and March 2007. Dr Wayne Jonas of the Samueli Institute is assisting us at ICT in organizing a special issue for December on the topic of research in complex healing modalities in cancer, with a special focus on homeopathy. The issue will include overview articles on methods of clinical research in complex systems. A second section will include articles on laboratory research in homeopathy in cancer. A point-counterpoint on lab studies of homeopathy and an Integrative Tumor Board that includes contributions by homeopathic and other physicians will also be included in what promises to be a lively issue.
In March 2007, Dr Kara Kelley, along with colleagues Janice Post-White and Elena Ladas, will guest edit a special issue on applications of silymarin in cancer Topics to be included are composition and pharmacokinetics of silymarin, mechanism of action, physiological actions in the liver, cancer chemopreventive potential, clinical trials, potential clinical applications, and thoughts for the future. We are looking forward to both of these special issues with great anticipation and expect them to be of major interest to our readers. 
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